Literature DB >> 20006709

Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris.

Chang-Han Lee1, Dong-Ki Choi, Hye-Ji Choi, Moo-Young Song, Yong-Sung Kim.   

Abstract

The neonatal Fc receptor (FcRn) is a non-covalently associated heterodimeric protein composed of a transmembrane anchored heavy chain (alphaFcRn) and a soluble light chain beta2-microglobulin (beta2m). In addition to its role in the transfer of maternal immunoglobulin Gs (IgGs) to the fetus, FcRn plays a key role in prolonging the serum half-life of IgGs in vivo. Herein, we report a strategy for functional expression of soluble human FcRn (shFcRn) in Pichia pastoris using a two-promoter vector system, where alphaFcRn and beta2m are co-expressed under their respective promoters in a single vector. The purified shFcRn from the culture supernatants correctly assembled to form the heterodimer with the typical secondary structures. At acidic pHs between 5.0 and 6.4, shFcRn exhibited substantial binding to the four subclasses of human IgGs at acidic pHs between 5.0 and 6.4, but at pHs between 6.8 and 8.0, its binding was negligible binding. No cross-reactivity with mouse IgG was exhibited even at acidic pH. This was consistent with the pH-dependent binding profiles of the shFcRn prepared from the mammalian cell expression. Furthermore, the shFcRn exhibited about 10-fold higher binding affinity with the tumor necrosis factor-alpha antagonists of monoclonal antibodies Infliximab and Adalimumab than that of Etanercept, providing a clue to their different serum half-lives in vivo. Our results suggest that the functionally expressed shFcRn from Pichia can be used for the biochemical and biological studies and as a screening probe for Fc engineering of human IgGs. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006709     DOI: 10.1016/j.pep.2009.12.004

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.

Authors:  Yang Feng; Rui Gong; Dimiter S Dimitrov
Journal:  Protein Expr Purif       Date:  2011-03-29       Impact factor: 1.650

Review 2.  Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.

Authors:  Ji-Hee Ha; Jung-Eun Kim; Yong-Sung Kim
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

Review 3.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

4.  Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.

Authors:  Jan Visser; Isabel Feuerstein; Thomas Stangler; Timo Schmiederer; Cornelius Fritsch; Martin Schiestl
Journal:  BioDrugs       Date:  2013-10       Impact factor: 5.807

5.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

6.  Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP.

Authors:  Johan Seijsing; Malin Lindborg; John Löfblom; Mathias Uhlén; Torbjörn Gräslund
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

7.  Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening.

Authors:  Hye-Ji Choi; Ye-Jin Kim; Dong-Ki Choi; Yong-Sung Kim
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.